Poitiers, France
- Featured
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation
* Phase 1 dose escalation of MRTX849 to determine maximum tolerated dose. * Phase 1b expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 to recommend Phase 2 regimens. * Separate Phase 2 cohorts of patients stratified by histological diagnosis for evaluation of clinical activity of MRTX849. * MRTX849 will be administered orally in a continuous regimen. The **Pilot Phase 1b Combination with Pembrolizumab** arm of the study will evaluate the safety, tolerability, PK, and clinical activity of the investigational study agent, MRTX849, in combination with pembrolizumab in patients with NSCLC. The **Pilot Phase 1b Combination with Cetuximab** arm of the study will evaluate the safety, tolerability, PK, and clinical activity of MRTX849 in combination with cetuximab in patients with CRC. Lastly, the **Pilot Phase 1b Combination with Afatinib** arm of the study will evaluate the safety, tolerability, PK and clinical activity of MRTX849 in combination with afatinib in patients with NSCLC.
Phase
1/2Span
Sponsor
Orange, California
Recruiting
- Featured
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)
For more information, please contact Incyte Corporation at 1.855.463.3463 or visit **[www.incyteclinicaltrials.com](https://www.incyteclinicaltrials.com/)**
Phase
3Span
Sponsor
Orange, California
Recruiting
- Featured
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
* Interventional Study * Estimated Enrollment:170 participants * Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations. * This study consists of 3 cohorts that will have study drug administered in parallel, Cohort A, Cohort B, and Cohort C. * There is no difference in the treatment regimen between the cohorts.
Phase
2Span
Sponsor
Orange, California
Recruiting
- Featured
Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy
Phase
3Span
Sponsor
Flamel Ireland LimitedOrange, California
Recruiting
- Featured
A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
* Phase 1/1b to establish the maximum tolerated dose of the combination of study drugs in patients with advanced solid tumor malignancies with a KRAS G12C mutation. * Phase 2 to evaluate clinical activity of the combination of study drugs in selected solid tumor malignancies with KRAS G12C mutation.
Phase
1/2Span
Sponsor
Orange, California
Recruiting
- Featured
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
Phase
2Span
140 weeksSponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.Orange, California
Recruiting
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
Phase
N/ASpan
183 weeksSponsor
Persephone BiosciencesOrange, California
Recruiting
Healthy Volunteers
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants with Early Alzheimer's Disease
Phase
1/2Span
117 weeksSponsor
Voyager TherapeuticsOrange, California
Recruiting
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Phase
3Span
132 weeksSponsor
Neurocrine BiosciencesOrange, California
Recruiting